Dexfenfluramine
- Generic Name
- Dexfenfluramine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H16F3N
- CAS Number
- 3239-44-9
- Unique Ingredient Identifier
- E35R3G56OV
- Background
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
- Indication
For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet
- Associated Conditions
- -
- Associated Therapies
- -
Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2011-12-15
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 50
- Registration Number
- NCT01296802
- Locations
- 🇨ðŸ‡
University Hospital of Psychiatry Zurich, Zurich, ZH, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath